Devyser announced the launch of next generation chimerism analysis solution, strengthening its offering in post-transplant monitoring

One Lambda™ Devyser Chimerism Plus is a next generation solution for chimerism analysis following allogeneic hematopoietic stem cell transplantation (HSCT). Building on the proven performance of the existing assay for chimerism monitoring, this assay features an innovative assay design that reduces the risk of errors associated with complex testing workflows while improving laboratory efficiency and ease of use.

"The launch of One Lambda Devyser Chimerism Plus is an important step in our collaboration with Thermo Fisher Scientific," said Jan Wahlström, CEO of Devyser. "We are happy to provide laboratories with a robust solution for chimerism monitoring while expanding our commercial opportunities in the market."

This launch builds on the established collaboration between Devyser and Thermo Fisher Scientific and expands the company's offering through Thermo Fisher Scientific's established commercial network.

"This launch expands our presence in the market and supports our growth ambitions in the coming year," added Michael Ulhin, CSO, Devyser.

"We are pleased to continue collaborating with Devyser to support laboratories performing chimerism analysis," said Tina Liedtky, president of the transplant diagnostics business at Thermo Fisher Scientific. "The launch of One Lambda Devyser Chimerism Plus reflects our shared commitment to providing laboratories with solutions that help streamline post-transplant monitoring workflows while delivering the reliable results clinicians need to support patient care.”

Disclaimer: One Lambda Devyser Chimerism Plus is for research use only (RUO). Not for use in diagnostic procedures.

For more information, please contact:
Jan Wahlström, CEO
Email: ir@devyser.com
Telephone: +46 8 562 158 50

About Devyser
Devyser is redefining how laboratories approach genetic testing. As your true one-stop shop, we offer streamlined solutions for a wide range of conditions, helping labs overcome complexity, reduce turnaround times, and maximize efficiency. 

Our technologies simplify workflows, minimize hands-on time, and deliver fast, accurate results. Every test is designed to empower labs to do more with less, freeing up resources while supporting better patient outcomes. 

We specialize in diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories - two critical areas where accuracy and speed matter. With customers in 65+ countries, we also operate our own CLIA-certified laboratory, Devyser Genomic Laboratories, in Atlanta and maintain sales offices across Europe and the US. 

Devyser is committed to regulatory excellence under IVDR, ensuring the highest quality standards across our growing product portfolio. 

Founded in 2004 and headquartered in Stockholm, Devyser is listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). Redeye Nordic Growth AB is the company's Certified Adviser.

Attachments
Devyser announced the launch of next generation chimerism analysis solution, strengthening its offering in post-transplant monitoring